RxDoctor Payments Data

Lindsay Cole, APRN

Family · Cincinnati, OHNPI 1750929279

Payments from drug & device makers

$2,237in general payments, 2019–2025

Across 36 payments — averaging $62.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Abbott$318
  • Boehringer Ingelheim$102
  • Novartis$95
  • Atricure, Inc.$66
  • Amgen$58
  • plus $149 from 7 others

What the payments were for

  • Travel & lodging$99344%
  • Food & beverage$1,24456%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,237 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$27,439
Medicare patients
258
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$119,985
EntrestoSacubitril/Valsartan70$77,375
XareltoRivaroxaban62$53,274
JardianceEmpagliflozin33$27,834
BrilintaTicagrelor23$21,118
Repatha SureclickEvolocumab16$12,005
Metoprolol Succinate300$2,409
Ranolazine ErRanolazine14$2,130
Rosuvastatin Calcium165$1,867
Torsemide114$1,732
Valsartan68$1,648
Atorvastatin Calcium206$1,361
Isosorbide Mononitrate ErIsosorbide Mononitrate144$1,329
Ezetimibe57$1,112
Nitroglycerin50$1,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$95$77,37570 claims
Johnson & JohnsonXarelto$13$53,27462 claims
Boehringer IngelheimJardiance$102$27,83433 claims
AstraZenecaBrilinta$30$21,11823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →